Cargando…

Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol

BACKGROUND: Between 30 and 50% of patients with major depressive disorder (MDD) do not respond sufficiently to antidepressant regimens. The conventional pharmacological treatments predominantly target serotonergic brain signaling but better tools to predict treatment response and identify relevant s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Köhler-Forsberg, Kristin, Jorgensen, Anders, Dam, Vibeke H., Stenbæk, Dea Siggaard, Fisher, Patrick M., Ip, Cheng-Teng, Ganz, Melanie, Poulsen, Henrik Enghusen, Giraldi, Annamaria, Ozenne, Brice, Jørgensen, Martin Balslev, Knudsen, Gitte Moos, Frokjaer, Vibe Gedsoe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391965/ https://www.ncbi.nlm.nih.gov/pubmed/32792991 http://dx.doi.org/10.3389/fpsyt.2020.00641

Ejemplares similares

Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study
por: Dam, Vibeke Høyrup, et al.
Publicado: (2022)

Sexual health and serotonin 4 receptor brain binding in unmedicated patients with depression—a NeuroPharm study
por: Rasmussen, Annika Læbo, et al.
Publicado: (2023)

The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study
por: Larsen, Søren Vinther, et al.
Publicado: (2022)

Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study
por: Köhler-Forsberg, Kristin, et al.
Publicado: (2022)

Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: a NeuroPharm study
por: Dam, V. H., et al.
Publicado: (2021)

Generalizability of treatment outcome prediction in major depressive disorder using structural MRI: A NeuroPharm study
por: Beliveau, Vincent, et al.
Publicado: (2022)

Stress Hormone Dynamics Are Coupled to Brain Serotonin 4 Receptor Availability in Unmedicated Patients With Major Depressive Disorder: A NeuroPharm Study
por: Vulpius, Gunild M, et al.
Publicado: (2023)

Stress-Hormone Dynamics and Working Memory in Healthy Women Who Use Oral Contraceptives Versus Non-Users
por: Høgsted, Emma Sofie, et al.
Publicado: (2021)

No evidence for a role of the serotonin 4 receptor in five-factor personality traits: A positron emission tomography brain study
por: Stenbæk, Dea Siggaard, et al.
Publicado: (2017)

Brain serotonin transporter is associated with cognitive‐affective biases in healthy individuals
por: Armand, Sophia, et al.
Publicado: (2022)

Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
por: Søndergaard, Anna, et al.
Publicado: (2022)

Trait aggression is associated with five‐factor personality traits in males
por: Dam, Vibeke H., et al.
Publicado: (2021)

Deep phenotyping towards precision psychiatry of first-episode depression — the Brain Drugs-Depression cohort
por: Jensen, Kristian Høj Reveles, et al.
Publicado: (2023)

Default mode network functional connectivity negatively associated with trait openness to experience
por: Marstrand-Joergensen, Maja Rou, et al.
Publicado: (2021)

Genetic contributions to brain serotonin transporter levels in healthy adults
por: Bruzzone, Silvia Elisabetta Portis, et al.
Publicado: (2023)

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation
por: Burmester, Daniel Rødbro, et al.
Publicado: (2022)

Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression
por: Jorgensen, Anders, et al.
Publicado: (2022)

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals
por: McCulloch, Drummond E-Wen, et al.
Publicado: (2021)

Brain serotonin 4 receptor binding is inversely associated with verbal memory recall
por: Stenbæk, Dea S., et al.
Publicado: (2017)

Psychometric Properties of the Verbal Affective Memory Test-26 and Evaluation of Affective Biases in Major Depressive Disorder
por: Hjordt, Liv V., et al.
Publicado: (2020)

Association between brain serotonin 4 receptor binding and reactivity to emotional faces in depressed and healthy individuals
por: Sankar, Anjali, et al.
Publicado: (2023)

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report
por: McCulloch, Drummond E-Wen, et al.
Publicado: (2022)

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
por: Jensen, Mathias Ebbesen, et al.
Publicado: (2022)

Psychometric Properties and Validation of the EMOTICOM Test Battery in a Healthy Danish Population
por: Dam, Vibeke H., et al.
Publicado: (2019)

Editorial: The psychotherapeutic framing of psychedelic drug administration
por: Beckman, Maria, et al.
Publicado: (2023)

Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
por: Høgh, Stinne, et al.
Publicado: (2021)

The technology of pharming
por: Rehbinder, Eckard, et al.
Publicado: (2009)

Cognitive impairment and psychopathology in out-of-hospital cardiac arrest survivors in Denmark: The REVIVAL cohort study protocol
por: Wagner, Mette Kirstine, et al.
Publicado: (2020)

Legal problems of pharming
por: Rehbinder, Eckard, et al.
Publicado: (2009)

Association of neurocognitive function with psychiatric hospitalization and socio-demographic conditions in individuals with bipolar and major depressive disorders
por: Sankar, Anjali, et al.
Publicado: (2023)

Hot and Cold Cognitive Disturbances in Parkinson Patients Treated with DBS-STN: A Combined PET and Neuropsychological Study
por: Jørgensen, Louise M., et al.
Publicado: (2022)

Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case–control study
por: Jorgensen, Anders, et al.
Publicado: (2015)

Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives
por: Messell, Catharina, et al.
Publicado: (2022)

Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial
por: Petersen, Jeff Zarp, et al.
Publicado: (2018)

Fat pharms.
por: Ma, M
Publicado: (1996)

Oral contraceptives and the serotonin 4 receptor: a molecular brain imaging study in healthy women
por: Larsen, S. V., et al.
Publicado: (2020)

The Evolution of PharmVar
por: Gaedigk, Andrea, et al.
Publicado: (2018)

Open and Calm – A randomized controlled trial evaluating a public stress reduction program in Denmark
por: Jensen, Christian G., et al.
Publicado: (2015)

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT(2A) Receptor Density in the Pig Brain
por: Raval, Nakul Ravi, et al.
Publicado: (2021)

Serotonin transporter gene (SLC6A4) variation and sensory processing sensitivity—Comparison with other anxiety‐related temperamental dimensions
por: Licht, Cecilie L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ve8hti54cr0g4nt16o9kf64jlq